These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17329908)

  • 21. DX-9065a, a specific factor Xa inhibitor, as a universal anticoagulant for blood collection tubes.
    Kumura T; Hino M; Yamane T; Tominaga K; Tatsumi N
    Clin Chim Acta; 2000 Apr; 294(1-2):27-35. PubMed ID: 10727670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
    Tanabe K; Morishima Y; Shibutani T; Terada Y; Hara T; Shinohara Y; Aoyagi K; Kunitada S; Kondo T
    Thromb Haemost; 1999 May; 81(5):828-34. PubMed ID: 10365760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enteric-coated tablets improve oral bioavailability of DX-9065, a novel anticoagulant.
    Fujii Y; Kanamaru T; Kikuchi H; Yamashita S; Sakuma S
    Eur J Pharm Sci; 2011 Mar; 42(4):392-9. PubMed ID: 21238588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats.
    Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
    Semin Thromb Hemost; 1996; 22(3):255-9. PubMed ID: 8836010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
    Gerbutavicius R; Iqbal O; Messmore HL; Wehrmacher WH; Hoppensteadt DA; Gerbutaviciene R; Griniute R; Fareed J
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):317-23. PubMed ID: 14653441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
    Tanabe K; Terada Y; Shibutani T; Kunitada S; Kondo T
    Thromb Res; 1999 Oct; 96(2):135-43. PubMed ID: 10574591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
    Rogers KL; Chi L; Rapundalo ST; Kramer JB; Gallagher KP
    Basic Res Cardiol; 1999 Feb; 94(1):15-22. PubMed ID: 10097826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
    Dyke CK; Becker RC; Kleiman NS; Hochman JS; Bovill EG; Lincoff AM; Gerstenblith G; Dzavik V; Gardner LH; Hasselblad V; Zillman LA; Shimoto Y; Robertson TL; Kunitada S; Armstrong PW; Harrington RA
    Circulation; 2002 May; 105(20):2385-91. PubMed ID: 12021225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats.
    Kaiser B; Paintz M; Scholz O; Kunitada S; Fareed J
    Thromb Res; 2000 Apr; 98(2):175-85. PubMed ID: 10713319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Photodecarboxylation of DX-9065a, a new factor Xa inhibitor, in aqueous solution.
    Kawai Y; Matsubayashi K
    Chem Pharm Bull (Tokyo); 1998 Jan; 46(1):131-5. PubMed ID: 9468645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
    Chino D; Fujita Y; Ishii K; Nakayama K
    J Pharmacol Sci; 2003 Apr; 91(4):319-29. PubMed ID: 12719661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats.
    Hara T; Yokoyama A; Tanabe K; Ishihara H; Iwamoto M
    Thromb Haemost; 1995 Aug; 74(2):635-9. PubMed ID: 8584999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat.
    Iba T; Kidokoro A; Fukunaga M; Fuse S; Suda M; Kunitada S; Hara T
    Shock; 2002 Feb; 17(2):159-62. PubMed ID: 11837793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
    Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioimmunoassay method for DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma.
    Murayama N; Tanaka S; Kikuchi T; Nakaoka M; Sudo K
    J Pharm Biomed Anal; 1996 Aug; 14(11):1435-45. PubMed ID: 8877849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
    Rezaie AR
    Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft.
    Kim DI; Kambayashi J; Shibuya T; Sakon M; Kawasaki T
    J Atheroscler Thromb; 1996; 2(2):110-6. PubMed ID: 9225218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin.
    Shimbo D; Osende J; Chen J; Robbins J; Shimoto Y; Kunitada S; Fuster V; Badimon JJ
    Thromb Haemost; 2002 Nov; 88(5):733-8. PubMed ID: 12428086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation.
    Tanaka M; Arai H; Liu N; Nogaki F; Nomura K; Kasuno K; Oida E; Kita T; Ono T
    Kidney Int; 2005 Jun; 67(6):2123-33. PubMed ID: 15882255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aminoalkylmethacrylate copolymer E improves oral bioavailability of YM466 by suppressing drug-bile interaction.
    Takemura S; Kondo H; Watanabe S; Sako K; Ogawara K; Higaki K
    J Pharm Sci; 2013 Sep; 102(9):3128-35. PubMed ID: 23459999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.